[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-multiple-sclerosis-pms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-multiple-sclerosis-pms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100654794","phase-1-a-safety-and-efficacy-study-evaluating-ctx112-in-subjects-with-refractory-neurologic-autoimmune-disease-100654794",false,"NCT07804004","A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease","A Phase 1\u002F2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Refractory Neurologic Autoimmune Disease.","CRSP-AID-502","Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C70 years at screening.\n2. Body weight \\>40 kg.\n3. Participants must voluntarily sign a written informed consent and be willing and able to comply with all trial requirements. Legal authorized representative, additional assent and witness may be used as appropriate.\n4. Adequate hematologic, renal, liver, cardiac and pulmonary function.\n5. Participants must agree to use acceptable methods of contraception.\n6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures.\n7. Confirmed diagnosis of PMS, relapsing NMOSD, relapsing MOGAD, refractory AIE, and refractory SPS\n\nExclusion Criteria:\n\n1. Prior treatment with any gene therapy or genetically modified cell therapy.\n2. Prior solid organ (e.g., heart, liver, kidney, lung) transplant or hematopoietic cell transplant.\n3. Presence of another clinically significant central nervous (CNS) pathology or another condition that in the opinion of the investigator may increase CART cell-related toxicities or confound disease assessments for the main indication.\n4. Presence of other active autoimmune disease or other conditions that are likely to pose increased safety risks and\u002For confound disease assessments, or pose significant risk to those receiving CART cell therapy.\n5. Presence or history of certain bacterial, viral or fungal infection.\n6. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).\n7. History or current diagnosis that requires uninterrupted, ongoing anticoagulation.\n8. Pregnant or lactating.\n9. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.\n10. History of suicide attempts within 3 years prior to screening.\n11. Any contraindications to lumbar puncture or MRI scans","ALL","18 Years","70 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This is a single-arm, open-label, multicenter, ascending dose Phase 1\u002F2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antiody-Associated Disease, refractory AutoImmune Encephalitis, and refractory Stiff Person Syndrome",[29,30,31,32,33],"Progressive Multiple Sclerosis (PMS)","Neuromyelitis Optica","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Autoimmune Encephalitis","Stiff-Person Syndrome",[35,36,37,38,39,40,41,42,43,44],"CD19","CTX112","Zugocabtagene geleucel","zugo-cel","CAR-T","PMS","Relapsing NMOSD","Relapsing MOGAD","Refractory AIE","Refractory SPS","NOT_YET_RECRUITING","2026-09-03",{"date":48,"type":49},"2026-09-09","ACTUAL",{"date":51,"type":22},"2026-09-15",{"date":53,"type":22},"2029-12-30",{"name":55,"class":56},"CRISPR Therapeutics","INDUSTRY",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100652997","phase-1-a-basket-study-of-cta313-in-participants-with-active-autoimmune-diseases-100652997","NCT07783269","A Basket Study of CTA313 in Participants With Active Autoimmune Diseases","A Single-Arm, Open-Label, Multi-Center, Phase Ib Basket Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTA313 in Participants With Active Autoimmune Diseases","ALLNEW","Key Inclusion Criteria:\n\n* Male or female, ≥ 18 and ≤ 75 years of age\n* Adequate organ function\n* Diagnosed with one of the following in addition to meeting disease-specific criteria:\n\n  1. Refractory Systemic Lupus Erythematosus (SLE) defined as an inadequate response to at least two immunomodulatory agents and one biologic agent\n  2. Primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)\n  3. Autoimmune Encephalitis (AIE)\n\nKey Exclusion Criteria:\n\n* Coexisting autoimmune diseases that could interfere with the attribution of disease activity or pose an increased safety risk\n* Participants with the following cardiac conditions are excluded:\n\n  1. History of heart failure New York Heart Association (NYHA) class III or IV;\n  2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.\n* History of severe central nervous system (CNS) disorders that could compromise the participant's ability to comply with protocol requirements or interfere with the accuracy of study assessments\n* Current or prior malignancy unless the malignancy was treated with curative intent and the subject has no known active malignant disease present for ≥ 5 years before enrollment\n* Primary immune deficiency\n* Presence of uncontrolled infections\n* History of untreated hepatitis C virus, or syphilis\n* History of HIV infection, or active or latent hepatitis B virus (HBV) infection.\n* Evidence of active Epstein-Barr virus (EBV), cytomegalovirus (CMV) or tuberculosis (TB)\n* History of prior CAR-T cell therapy or any other genetically modified immune cell therapy\n* Having received live\u002Fattenuated vaccine within 4 weeks prior to enrollment\n* Participants with a history of hypersensitivity to tacrolimus\n* Those who have participated in other interventional clinical trials within 30 days before enrollment\n* Participants who meet disease-specific exclusionary criteria as specified","75 Years",{"count":67,"type":22},81,[25],"The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.\n\nParticipants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate.\n\nParticipants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313.\n\nPatients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.",[71,29,32],"Systemic Lupus Erthematosus (SLE)",[73],"allogeneic CAR-T Therapy","2026-08-19",{"date":76,"type":49},"2026-08-24",{"date":78,"type":22},"2026-12",{"date":80,"type":22},"2029-09",{"name":82,"class":56},"Imviva Bio"]